Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Time as a factor in thrombolytic therapy.

D G Julian1

  • 1British Heart Foundation, London, U.K.

European Heart Journal
|August 1, 1990
PubMed
Summary
This summary is machine-generated.

Early thrombolytic therapy for myocardial infarction improves reperfusion and preserves heart function. Faster treatment initiation is crucial for better patient outcomes, though optimal timing requires further investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Management of Dysrhythmias in Cardiac Infarction.

Journal of the Royal College of Physicians of London·2019
Same author

Translation of clinical trials into clinical practice.

Journal of internal medicine·2004
Same author

Myocardial infarction: is evidence-based medicine the best?

Lancet (London, England)·2002
Same author

The evolution of the coronary care unit.

Cardiovascular research·2001
Same author

[Legal implications of medical guidelines. A Task Force of the European Society of Cardiology].

Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2001
Same author

Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT)

Lancet (London, England)·2000

Area of Science:

  • Cardiology
  • Emergency Medicine
  • Pharmacology

Background:

  • Angiographic studies show earlier thrombolysis improves reperfusion and patency rates.
  • Previous research suggests early therapy reduces infarct size and preserves left ventricular function.
  • Major thrombolytic trials (GISSI, ISIS-2) highlight the importance of prompt treatment after symptom onset.

Purpose of the Study:

  • To evaluate the impact of early versus delayed thrombolytic therapy on myocardial infarction outcomes.
  • To clarify the relationship between treatment timing and reperfusion, infarct size, and left ventricular ejection fraction (LVEF).

Main Methods:

  • Review of angiographic studies and major intravenous thrombolytic mortality trials (GISSI, ISIS-2).
  • Analysis of findings from a small trial with alteplase in Belfast.

Related Experiment Videos

  • Consideration of the design and expected outcomes of the European Myocardial Infarction Project (EMIP).

    • Main Results:

    • Earlier thrombolysis is associated with greater reperfusion and patency rates.
    • Evidence suggests early treatment preserves left ventricular function and reduces infarct size.
    • Discrepancies exist between reported trial benefits and physiological findings, possibly due to patient selection for late entry.

    Conclusions:

    • Prompt initiation of thrombolytic therapy is critical for improving outcomes in myocardial infarction.
    • Further research, like the EMIP, is needed to definitively establish the benefits of early intervention.
    • Current treatment delays in many European cities (5-6 hours) indicate a need for faster access to care.